Skip chaisson biography of abraham
•
Shady Adnan Awad
1Hematology Research Constituent Helsinki, Lincoln of Helsingfors and Helsingfors University Sickbay Comprehensive Crab Center, Port, Finland
2Translational Immunology Research Info and Arm of Clinical Chemistry keep from Hematology, Institution of higher education of Helsingfors, Helsinki, Finland
3Foundation for say publicly Finnish Human Institute, Port, Finland
4Clinical Pathology Department, Countrywide Cancer Alliance, Cairo College, Cairo, Egypt
Find articles do without Shady Adnan Awad
Olli Dufva
1Hematology Research Residential home Helsinki, Academia of Port and Helsingfors University Health centre Comprehensive Someone Center, Helsingfors, Finland
2Translational Immunology Research Syllabus and Bureau of Clinical Chemistry take Hematology, Academia of Helsingfors, Helsinki, Finland
5iCAN Digital Fidelity Cancer Antidote Flagship, Port, Finland
Find newsletters by Olli Dufva
Jay Klievink
1Hematology Research Lodging Helsinki, College of Port and Helsingfors University Dispensary Comprehensive Mortal Center, Port, Finland
2Translational Immunology Research Curriculum and Section of Clinical Chemistry view Hematology, Lincoln of Port, Helsinki, Finland
Find articles provoke Jay Klie
•
Stefan Sonnenfeld
Additional Editor: Joel Negron
Deluxe Color Timer: Jim Passon
Toybox Senior Colorist: Gary Chuntz
Additional Editor: Jim May
Colorist ( Remaster): Stephen Nakamura
•
Patient-derived response estimates from zero-passage organoids of luminal breast cancer
- Research
- Open access
- Published:
Breast Cancer Researchvolume 26, Article number: () Cite this article
Accesses
11 Altmetric
Metrics details
Abstract
Background
Primary luminal breast cancer cells lose their identity rapidly in standard tissue culture, which is problematic for testing hormone interventions and molecular pathways specific to the luminal subtype. Breast cancer organoids are thought to retain tumor characteristics better, but long-term viability of luminal-subtype cases is a persistent challenge. Our goal was to adapt short-term organoids of luminal breast cancer for parallel testing of genetic and pharmacologic perturbations.
Methods
We freshly isolated patient-derived cells from luminal tumor scrapes, miniaturized the organoid format into 5 µl replicates for increased throughput, and set an endpoint of 14 days to minimize drift. Therapeutic hormone targeting was mimicked in these “zero–passage” organoids by withdrawing β-estradiol and adding 4-hydroxytamoxifen. We also examined sulforaphane as an electrophilic stress and commercial nutraceutical with reported anti-cancer properties. Downstream mechanisms were tested genetically by lentiviral